Recently, EMPA-REG OUTCOME trial provides the evidence that SGLT2 inhibition with empagliflozin significantly reduces cardiovascular events and heart failure hospitalization in type 2 diabetic patients at high risk [12–14, 38]. The gene discussed is SLC5A2; the disease is heart failure.